Dermatology

Learn about the role of biofilms in skin disorders like acne, atopic dermatitis, and chronic wounds. This article explores how biofilms contribute to disease pathogenesis, their resistance to antibiotics, and the latest conventional and innovative treatments aimed at targeting biofilm-associated skin conditions.

Update on Ruxolitinib phosphate cream 1.5% (Opzelura®), Roflumilast foam 0.3% (Zoryve®), Clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% fixed-dose topical gel (Cabtreo™), Lebrikizumab-lbkz (Ebglyss™ SC injection), Ustekinumab-srlf (Imuldosa™ SC/IV injection), Ustekinumab-aauz (Otulfi™ SC/IV injection), Ustekinumab biosimilar (Pyzchiva™ SC/IV injection).

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes.

Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®).

Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.

Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects.

Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™).